This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.3.2.1070 HL7 v3 Value Set substanceAdminSubstitution

This value set (http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution) is defined as part of HL7 v3.

Summary

Defining URL:

http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution

Name:

v3 Code System substanceAdminSubstitution

Definition:

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

OID:

(for OID based terminology systems)

Source Resource

XML / JSON

This value set is used in the following places:

This value set is the designated 'entire code system' value set for v3 Code System substanceAdminSubstitution

4.3.2.1070.1 Content Logical Definition

This value set includes codes from the following code systems:

Include all codes defined in http://hl7.org/fhir/v3/substanceAdminSubstitution

4.3.2.1070.2 Expansion

This expansion generated 06 Dec 2016

This value set contains 9 concepts

Expansion based on http://hl7.org/fhir/v3/substanceAdminSubstitution version 2016-11-11

All codes from system http://hl7.org/fhir/v3/substanceAdminSubstitution

Code	Display	Definition
_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
EC	equivalent composition	Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
BC	brand composition	Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.
N	none	No substitution occurred or is permitted.